$26.860
+0.782 (+2.91%)收盤時
SGP 同業比較
In the context of the broader market, SGP competes directly with industry leaders such as FTH and CLYM. With a market capitalization of $876.34M, it holds a significant position in the sector. When comparing efficiency, SGP's gross margin of N/A stands against FTH's N/A and CLYM's N/A. Such benchmarking helps identify whether SpyGlass Pharma, Inc. is trading at a premium or discount relative to its financial performance.
SpyGlass Pharma Inc 財務表現
The company reported a net loss of $19.9 million for Q2 2026, a significant increase from the previous year, indicating rising expenses. However, the current ratio remains strong at 25.06, suggesting good short-term liquidity.
Financials
FY2026Q2
-21.97M
Operating Profit
FY2026Q1
-13.82M
Net Income after Tax
FY2026Q1
-0.69
EPS - Diluted
FY2026Q1
-14.22M
Free Cash Flow
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。